Marc Machaalani, MD, on soluble MAdCAM-1 in metastatic renal cell carcinoma
Commentary on the clinical relevance of soluble MAdCAM-1 in metastatic renal cell carcinoma.
Video Interviews
Soluble MAdCAM-1 as a prognostic biomarker in metastatic RCC
Featured interview at ESMO 2025 discussing the role of soluble MAdCAM-1 as a prognostic biomarker in metastatic renal cell carcinoma.
Dr Machaalani on the potential role of circulating KIM-1 as a biomarker in metastatic RCC
Discussion on the emerging role of circulating KIM-1 as a biomarker in metastatic renal cell carcinoma.
Characterization of circulating KIM-1: correlation with protein levels and tumor biology in metastatic RCC
Analysis of the biological and clinical correlates of circulating KIM-1 in metastatic renal cell carcinoma.
Dr Machaalani on the incidence of ERBB2 amplifications across race, sex, and cancer type
Discussion on ERBB2 amplification patterns across demographic and cancer subtypes.
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Video feature on ERBB2 amplification patterns and implications for HER2-targeted therapies.
Dr Machaalani on overcoming acquired resistance through AXL and c-MET inhibition in RCC
Discussion on targeting AXL and c-MET pathways to overcome acquired resistance in renal cell carcinoma.
Immune signatures as predictors for immunotherapy regimens in metastatic RCC
Discussion on host immune signatures as predictive biomarkers for immunotherapy response in metastatic RCC.
Articles
Low KIM-1 levels are associated with improved clinical outcomes in advanced RCC
Coverage on the clinical implications of low circulating KIM-1 levels in advanced renal cell carcinoma.
Elevated KIM-1 levels are associated with poor prognosis in metastatic RCC
Report highlighting the prognostic implications of elevated circulating KIM-1 levels in metastatic renal cell carcinoma.
Immunotherapy rechallenge after prior immune checkpoint inhibition in mRCC
Commentary on immunotherapy rechallenge strategies after prior immune checkpoint inhibition in metastatic RCC.
Examining the evidence on immunotherapy rechallenge after prior ICI exposure in mRCC
ASCO Daily News feature analyzing the evidence for immunotherapy rechallenge in metastatic RCC.